Can cartilage actually regenerate? Why joint "repair" claims outrun the evidence

TL;DR

• Adult joint cartilage is close to permanent tissue. It has no blood supply and no nerves, and radiocarbon dating shows its collagen is laid down in youth and barely renewed afterwards, even in osteoarthritic knees.
• When cartilage is "repaired," it is usually replaced with a different tissue. Surgical marrow-stimulation techniques produce fibrocartilage, which is weaker than the original hyaline cartilage.
• The common knee injections change symptoms, not structure. In placebo-controlled trials, platelet-rich plasma did not beat saline on pain or cartilage volume, hyaluronic acid's benefit was too small to matter clinically, and repeated corticosteroid injections were linked to more cartilage loss.
• Peptides sold for joints, such as BPC-157 and TB-500 (the "Wolverine stack"), have animal data and one small uncontrolled human knee-pain review. Any cartilage benefit is unestablished rather than disproven, because the controlled human trials have not been funded or run, and some people explore them with a physician as an option alongside the established basics below.
• What does help is well established: exercise therapy and weight management improve pain and function in knee osteoarthritis, and surgeon-led cartilage procedures, including an FDA-approved cell-based implant, exist for suitable focal defects.

Educational content, not medical advice. No doses or protocols appear.

---

Someone with a painful knee is often told, directly or by implication, that the right injection will "regrow" or "rebuild" their cartilage. It is an appealing idea, and it is the claim in this area that the evidence supports least. This page explains why cartilage behaves differently from the other tissues covered in this cluster, what the injection trials have actually measured, and where the real options sit.

It is the third tissue page in a set. What actually helps a tendon heal covers tendon, which heals slowly. Bone fracture healing covers bone, which regenerates well. Cartilage is the exception to both: in adults it barely heals at all on its own.

Why cartilage is the exception - no blood supply, no nerves

The cartilage that lines the ends of bones inside joints is hyaline (articular) cartilage. It is a smooth, low-friction surface made mostly of water, type II collagen and large water-binding molecules called proteoglycans, maintained by a sparse population of cells called chondrocytes.

Three features make it unusual among the body's tissues:

No blood supply. Articular cartilage is avascular. It is nourished by diffusion from the joint fluid, helped along by the pumping effect of loading and unloading. Most tissues repair by bringing blood, cells and growth signals to the site of damage. Cartilage has no such delivery route.

No nerves. Cartilage is aneural, so the cartilage itself does not hurt. Pain in an arthritic knee comes from surrounding structures: bone under the cartilage, the joint lining, ligaments and the joint capsule. This is the single most important fact for interpreting injection claims, and it is returned to below.

Very slow turnover. The clearest evidence comes from radiocarbon left in the atmosphere by nuclear weapons testing in the 1950s and 1960s, which acts as a date stamp on tissue built at the time. A 2016 study in Science Translational Medicine applied it to knee cartilage from healthy adults and adults with osteoarthritis. The collagen carried the radiocarbon signature of the donor's adolescence, indicating that cartilage collagen is laid down during growth and essentially not renewed in adulthood. Osteoarthritis did not meaningfully increase that turnover. The same technique produced the comparable finding for the tendon core described on the tendon page.

So "can cartilage actually regenerate?" has a direct answer for adults: not meaningfully, on its own. That is the baseline against which any regeneration claim has to be judged.

What "repair" means when the tissue cannot regenerate (fibrocartilage vs hyaline)

Because hyaline cartilage does not regrow, "repair" in joint medicine usually means filling a defect with something else.

Fibrocartilage is the tissue the body produces when a cartilage defect reaches the bone underneath and bleeding brings in marrow cells. It is rich in type I collagen, like scar tissue, rather than the type II collagen of hyaline cartilage. It fills the hole, but it is mechanically weaker and less durable than the original surface.

Marrow stimulation (microfracture) is a surgical technique that deliberately creates small openings in the bone under a defect so that this fibrocartilage forms. It can relieve symptoms for suitable focal defects, but the repair tissue is fibrocartilage, not regenerated hyaline cartilage.

Cell-based procedures go further. In autologous chondrocyte implantation, a surgeon harvests a small amount of the patient's own cartilage, the cells are grown in a laboratory, and then implanted into the defect. In December 2016 the FDA approved MACI, a version in which the cultured cells are seeded onto a collagen membrane, for adults with symptomatic, full-thickness cartilage defects of the knee. In its pivotal trial it outperformed microfracture. It is a two-stage surgical procedure for selected focal defects, not a treatment for widespread osteoarthritis.

The key distinction is between a focal defect, a localised hole in otherwise reasonable cartilage, often after injury, and osteoarthritis, a whole-joint disease affecting cartilage, bone, lining and surrounding tissue. Surgical cartilage procedures are designed for the first. No procedure or injection has been shown to restore hyaline cartilage across an osteoarthritic joint.

Tendon, bone, cartilage: three different timelines

People often ask about "cartilage repair vs tendon healing" as if the two were the same problem on different schedules. They are different problems.

The table explains why tissue-general claims break down. A product that is said to "heal connective tissue" has not specified which tissue, and the tissues differ more in their repair capacity than in almost anything else.

What the injection evidence actually shows

The injections commonly offered for knee osteoarthritis have been tested in randomised trials, several against placebo injections. The pattern is consistent: some modest symptom effects, no convincing evidence of cartilage being rebuilt.

Platelet-rich plasma (PRP). The RESTORE trial, published in JAMA in 2021, randomised 288 adults with knee osteoarthritis to PRP or saline injections and followed them for 12 months. It measured both pain and medial tibial cartilage volume on MRI. There was no meaningful difference between PRP and saline on either outcome: both groups improved somewhat on pain, and both lost a similar small amount of cartilage volume. PRP preparations vary widely, a point covered in PRP, prolotherapy and peptide injections, so the fair summary is "unproven over placebo for knee osteoarthritis," not "proven useless for everything."

Hyaluronic acid (viscosupplementation). A 2012 meta-analysis in Annals of Internal Medicine pooled 89 randomised trials with more than 12,000 patients. In the larger, higher-quality trials the pain benefit was small enough to be judged clinically irrelevant, and the treatment was associated with a modestly higher risk of serious adverse events. Smaller, lower-quality trials reported bigger benefits, a common warning sign.

Corticosteroid. Steroid injections can relieve an inflamed, painful knee in the short term. A 2017 trial in JAMA gave 140 adults with knee osteoarthritis repeated steroid or saline injections over two years. Pain did not differ between the groups, and the steroid group had significantly greater cartilage volume loss. That does not rule out occasional short-term use under a clinician's judgement, but it is the opposite of a regeneration effect.

BPC-157 and TB-500. These investigational peptides are marketed for joint and cartilage repair. The supporting work is in cell culture and animal models. There are no controlled human trials measuring cartilage for either compound. A September 2026 UCLA Health review of the musculoskeletal peptide literature found most studies were animal-only and essentially none demonstrated significant clinical benefit in people. That is an absence of trials more than a record of failure: no one has funded the imaging-based, placebo-controlled studies that would answer the question, so any cartilage benefit is unestablished rather than disproven. Neither compound is approved for any joint indication. The wider picture is in what the BPC-157 injury evidence shows.

Stem cell injections are also widely advertised. Outside regulated clinical trials and approved products, these are not established treatments for osteoarthritis, and the same distinction between symptom change and structural change applies.

Why symptom relief and structural repair get conflated

Cartilage has no nerves, so a knee that hurts less does not mean cartilage has grown back. Pain in osteoarthritis tracks inflammation in the joint lining, changes in the bone beneath the cartilage, muscle strength, body weight, sleep, mood and expectation. An injection can influence several of those without touching the cartilage.

Several features of the evidence make the confusion easy:

1. Placebo injections are powerful in knee pain. In RESTORE and the steroid trial, the saline groups improved too. An uncontrolled before-and-after story cannot separate the injection from the needle, the attention and time.
2. Osteoarthritis symptoms fluctuate. People tend to seek treatment during a flare, and flares tend to settle, so improvement after any treatment is expected. How to read an injury study covers this regression effect in detail.
3. Structure is rarely measured. Most injection studies report pain scores. Few measure cartilage on MRI, and those that do, like RESTORE and the steroid trial, have not found regeneration.
4. Animal cartilage is not human osteoarthritis. Animal studies usually create a fresh, small defect in a young, healthy joint. Human osteoarthritis is a slow, whole-joint disease in older tissue.

Asking two separate questions keeps this straight: did symptoms improve more than with a placebo injection? and was cartilage measured, and did it change?

What is reasonable to expect

The honest picture is more constructive than the regeneration pitch, because the options that work do not depend on regrowing cartilage.

• Exercise therapy is a core treatment for knee osteoarthritis in major international guidelines. Strengthening and neuromuscular programmes improve pain and function, are low-risk, and are best designed and progressed by a physiotherapist.
• Weight management reduces load and inflammation in the joint. In the STEP 9 trial, semaglutide in people with obesity and knee osteoarthritis reduced knee pain more than placebo, an effect that appears to be largely weight-mediated. The detail is in GLP-1s and your joints.
• For a focal cartilage defect, often after injury and in a younger, otherwise healthy knee, an orthopaedic surgeon can assess whether a procedure such as microfracture or a cell-based implant like MACI is suitable.
• For advanced osteoarthritis that has not responded to these measures, joint replacement remains an established, effective option.

Reasonable expectations are about pain, function and keeping the joint working, not about turning back the cartilage itself. That is a realistic goal, and for most people it is achievable.

Why some people consider BPC-157 and TB-500 (the "Wolverine stack")

BPC-157 and TB-500 are often paired and nicknamed the "Wolverine stack". Given everything above, it is fair to ask why anyone considers them for a joint at all. The honest answer has five parts.

Natural healing is slow, and cartilage barely renews. As set out above, articular cartilage has no blood supply and its collagen is essentially not renewed in adulthood, while the tendons and ligaments around a joint heal over months. For someone facing a long recovery, the appeal of anything that might shorten it is easy to understand.

Animal studies suggest faster healing. In laboratory models, mostly rat tendon, ligament and muscle injuries, BPC-157 and TB-500 were associated with faster healing and shorter recovery. Those are encouraging signals, but they come from fresh, controlled injuries in young animals, which is a different situation from an older human knee with osteoarthritis.

The human knee data are very limited. The only published human knee data come from a 2021 retrospective chart review of BPC-157 injected into the knee. Seventeen patients were injected, 16 were reached by phone, and 14 of the 16 reported that their knee pain had improved. There was no control group, the outcomes were self-reported, and only four patients had an MRI, so the review cannot show whether cartilage changed or whether the peptide, rather than time and placebo, was responsible.

People report benefit. Many people report recovering faster on BPC-157 and TB-500. Those experiences are real to the people having them, but an individual report cannot separate the peptide from natural healing, a symptom flare settling, or placebo, which is exactly why controlled trials matter.

Regulatory status. Both compounds are investigational and not FDA-approved for any use. In July 2026 the FDA's Pharmacy Compounding Advisory Committee recommended both for the list of substances that compounding pharmacies may use. That vote is advisory, and neither has been added to the list yet.

So the honest framing is that the Wolverine stack is an option some people explore with a physician, not an established cartilage treatment. If you want to explore it, Vivre Labs recommends starting with baseline bloodwork, and treats it as something alongside exercise and load management, not instead of them. The compound pages are BPC-157 and TB-500, and the GLOW protocol pairs them with GHK-Cu. For the fuller evidence, see the BPC-157 and TB-500 stack and what the BPC-157 injury evidence shows.

Frequently asked questions

Can cartilage actually regenerate? In adults, not meaningfully on its own. Articular cartilage has no blood supply and no nerves, and radiocarbon studies show its collagen is laid down during growth and essentially not renewed afterwards, including in osteoarthritic knees. Deep defects can fill with fibrocartilage, and surgeons can implant cultured cartilage cells into selected focal defects, but no injection has been shown to regrow hyaline cartilage across an arthritic joint.

Do injections regrow cartilage? The evidence says no. PRP did not differ from saline on cartilage volume in a 12-month randomised trial, hyaluronic acid's pain benefit is small, and repeated steroid injections were linked to more cartilage loss than saline. Some people do feel better after injections, but symptom relief and structural repair are different outcomes.

Is there evidence for peptides for joint cartilage? Mostly from cell and animal studies, plus one small uncontrolled human chart review of knee pain that did not measure cartilage. BPC-157 and TB-500 have no controlled human trials measuring cartilage, and both are investigational and unapproved for any joint indication. Because those trials have not been funded or run, any benefit is unestablished rather than disproven, and some people explore them with a physician, as covered in the section on the Wolverine stack above.

How is cartilage repair different from tendon healing? Tendon heals, slowly, because it has some blood supply and cells that remodel under load. Articular cartilage has no blood supply at all and barely turns over in adults. That is why progressive loading can rebuild a tendon's capacity, while for cartilage the realistic aims are protecting the joint, improving strength and function, and surgery for suitable focal defects.

Related reading

• GLP-1s and your joints - the knee osteoarthritis trial evidence on weight loss
• Part of The Complete Guide to Recovery Peptides

---

Talk it through with a clinician first. A painful knee deserves a proper diagnosis, including whether the problem is a focal defect or osteoarthritis, and a plan built on exercise and load before anyone discusses an injection of any kind. Vivre Labs recommends starting with baseline bloodwork, so any decision starts with the evidence, not a product.

Educational content, not medical advice. This article does not recommend any injection, compound or procedure for any individual's joint. BPC-157 and TB-500 are investigational, are not approved for any joint or cartilage indication, and lack controlled human cartilage trials; the July 2026 FDA advisory committee recommendation on them is advisory only. Links to Vivre Labs compound and protocol pages lead to product information and are not a recommendation for any individual. MACI is an FDA-approved surgical product for selected cartilage defects of the knee in adults and is not a treatment for osteoarthritis generally. No doses, schedules, dosing protocols or exercise prescriptions appear on this page; exercise programmes should be designed and progressed by a qualified clinician. Claims for the Malaysian market are subject to MAB requirements. Position stated as of 20 October 2026.

References

• Cartilage turnover - Heinemeier KM, Schjerling P, Heinemeier J, et al. Radiocarbon dating reveals minimal collagen turnover in both healthy and osteoarthritic human cartilage. Science Translational Medicine. 2016;8(346):346ra90. (Knee cartilage from 8 healthy adults and 15 adults with osteoarthritis; collagen essentially not renewed after adolescence; no meaningful increase in osteoarthritis.) (aaas.org)
• PRP, RESTORE trial - Bennell KL, Paterson KL, Metcalf BR, et al. Effect of intra-articular platelet-rich plasma vs placebo injection on pain and medial tibial cartilage volume in patients with knee osteoarthritis: the RESTORE randomized clinical trial. JAMA. 2021;326(20):2021-2030. (288 participants; 12 months; no significant difference in pain or medial tibial cartilage volume.) (hcplive.com)
• Hyaluronic acid - Rutjes AWS, Jüni P, da Costa BR, Trelle S, Nüesch E, Reichenbach S. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Annals of Internal Medicine. 2012;157(3):180-191. (89 trials, 12,667 patients; clinically irrelevant pain benefit in large high-quality trials; higher risk of serious adverse events.) (aafp.org)
• Corticosteroid - McAlindon TE, LaValley MP, Harvey WF, et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA. 2017;317(19):1967-1975. (140 participants; two years; greater cartilage volume loss with steroid; no difference in pain.) (aafp.org)
• MACI - US FDA approval, December 2016, of autologous cultured chondrocytes on porcine collagen membrane (Vericel) for adults with symptomatic, full-thickness cartilage defects of the knee; pivotal SUMMIT trial versus microfracture (144 participants, two years, with extension). (rheum-live.com)
• STEP 9 - Bliddal H, Bays H, Czernichow S, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024. (See GLP-1s and your joints.)
• BPC-157 knee chart review - Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine. 2021. PMID 34324435. (Uncontrolled retrospective chart review; 17 patients injected, 16 surveyed by phone, 14 of 16 reported improved knee pain; subjective outcomes only, no control group, only 4 had MRI.) (asipp.org PDF)
• Peptide evidence base - UCLA Health / The American Journal of Sports Medicine, review published 8 September 2026 covering 565 studies across six unapproved peptides; more than two-thirds animal-only; essentially no studies demonstrating significant clinical benefit for musculoskeletal conditions. (uclahealth.org)
• Guideline context - International osteoarthritis guidelines (including OARSI) list exercise, education and weight management as core treatments for knee osteoarthritis.